Get the Stockscreener App
2.375
0.21%
0.005
InspireMD Inc. stock is traded at $2.375, with a volume of 58,643.
It is up +0.21% in the last 24 hours and down -5.38% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$2.37
Open:
$2.37
24h Volume:
58,643
Relative Volume:
0.36
Market Cap:
$99.09M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-2.2619
EPS:
-1.05
Net Cash Flow:
$-16.76M
1W Performance:
-5.00%
1M Performance:
-5.38%
6M Performance:
-25.55%
1Y Performance:
-16.67%
1-Day Range:
$2.36
$2.40
1-Week Range:
$2.35
$2.50
52-Week Range:
$1.99
$3.798
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.375 | 103.88M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD Inc. Breakout Confirmed by Volume MetricsJuly 2025 Momentum & Reliable Volume Spike Trade Alerts - newsimpact.co.kr
Is InspireMD Inc. stock undervalued right now2025 Key Lessons & AI Driven Price Forecasts - kangso.co.kr
Is InspireMD Inc. stock bottoming outJuly 2025 Drop Watch & Smart Allocation Stock Reports - Newser
Price action breakdown for InspireMD Inc.2025 Market Trends & Long-Term Growth Stock Strategies - Newser
Can a trend reversal in InspireMD Inc. lead to recoveryWeekly Market Report & Growth Focused Stock Pick Reports - Newser
Using data tools to time your InspireMD Inc. exitJuly 2025 Trends & Stock Portfolio Risk Management - Newser
InspireMD Inc. stock trend forecastJuly 2025 Momentum & Weekly Market Pulse Alerts - Newser
Will InspireMD Inc. stock recover after recent drop2025 EndofYear Setup & AI Enhanced Execution Alerts - Newser
Is InspireMD Inc. still worth holding after the dipJuly 2025 Price Swings & Expert Verified Movement Alerts - Newser
Is InspireMD Inc. forming a bottoming baseQuarterly Market Review & AI Enhanced Execution Alerts - Newser
Is a relief rally coming for InspireMD Inc. holders2025 Breakouts & Breakdowns & Real-Time Volume Triggers - Newser
Rosalind Advisors Expands Stake in InspireMD Inc. with Strategic Acquisition - AInvest
Will InspireMD Inc. Hold Gains Into CloseJuly 2025 Technicals & Low Volatility Stock Suggestions - sundaytimes.kr
Quant Models Detect Momentum Reversal in InspireMD Inc.July 2025 Sentiment & Safe Capital Growth Stock Tips - newsyoung.net
Global Embolic Protection Devices Market Set to Experience Unprecedented Growth at a CAGR of ~8% by 2032 | DelveInsight - GlobeNewswire Inc.
What earnings revisions data tells us about InspireMD Inc.Quarterly Profit Summary & Consistent Growth Stock Picks - Newser
Why InspireMD Inc. stock attracts strong analyst attentionFree Low Volatility Stable Growth Picks - Newser
What MACD signals say about InspireMD Inc.Summary of Trade Cycles in 5-Year Range - Newser
Bollinger Bands Show Potential Breakout in InspireMD Inc.Profit Focused Stock Screener Results Released - beatles.ru
Is InspireMD Inc. showing insider buyingExtreme Return Watchlist - sisaissue.com
InspireMD signals robust U.S. CGuard Prime launch progress and expands clinical pipeline following $58M capital infusion - MSN
InspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call Transcript - Insider Monkey
InspireMD Q2 Earnings: Revenue Down, CEO Confident in Future Growth - AInvest
InspireMD Reports Q2 2025 Financial Results and Milestones Amid FDA Approval and US Launch of CGuard Prime Carotid Stent System - AInvest
InsureMD Navigates Trade Policy Risks with US Manufacturing Plans - AInvest
InspireMD Inc (NSPR) Q2 2025 Earnings Call Highlights: Strategic US Launch Amid Financial Challenges - Investing.com Canada
InspireMD Inc. Navigates Trade Policy Risks with U.S. Manufacturing Plans - TipRanks
InspireMD Inc. Reports Q2 2025 Earnings and Regulatory Milestones - TipRanks
InspireMD’s Earnings Call: FDA Approval and Financial Challenges - TipRanks
InspireMD reports Q2 EPS (26c) vs (22c) last year - TipRanks
InspireMD's Strategic U.S. Expansion and Product Launch Momentum: A Balancing Act of Optimism and Caution - AInvest
InspireMD's Strategic Capital Raise and Clinical Innovation Position It as a High-Conviction Growth Play in the $5B+ U.S. Coronary Stent Market - AInvest
InspireMD's Q2 2025: Key Contradictions in FDA Approval, Product Launches, and U.S. Market Strategy - AInvest
InspireMD Experiences Robust US Launch Progress and Expands Clinical Pipeline Following $58M Investment - AInvest
InspireMD shares fall 1.50% intraday despite Q2 revenue beating estimates. - AInvest
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises - Investing.com Canada
Earnings call transcript: InspireMD Q2 2025 misses EPS forecast, stock rises By Investing.com - Investing.com South Africa
InspireMD earnings missed by $0.05, revenue fell short of estimates - Investing.com Canada
InspireMD Reports Q2 2025 Financial Results and Milestones - TipRanks
InspireMD's Q2 Results: Revenue Misses Expectations, GAAP EPS at -$0.26 - AInvest
InspireMD Announces Second Quarter 2025 Financial Results and Investor Conference Call Details - Quiver Quantitative
InspireMD gets FDA approval for CGuard Prime carotid stent system. - AInvest
InspireMD Reports Second Quarter 2025 Financial Results - GlobeNewswire
InspireMD Secures FDA Approval for Revolutionary Stroke Prevention Stent, Raises $58M for US Launch - Stock Titan
InspireMD Inc. Outperforms Peers on Volume MetricsTrade Ready Stock Watch for Short Term Published - metal.it
InspireMD, Inc. SEC 10-Q Report - TradingView
InspireMD's Q2 2025 Earnings and Strategic Momentum: A Path to Profitability Amid Uncertainty - AInvest
Does InspireMD Inc. stock perform well during market downturnsUnlock daily stock market insights for success - Jammu Links News
What makes InspireMD Inc. stock price move sharplyInvest confidently with daily market forecasts - Jammu Links News
What analysts say about InspireMD Inc. stockHigh-impact stock picks - Jammu Links News
What is the dividend policy of InspireMD Inc. stockUnlock powerful market analysis and alerts - Jammu Links News
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):